Tofacitinib for the treatment of moderate-to-severe psoriasis

Andrea Chiricozzi*, Sara Faleri, Rosita Saraceno, Luca Bianchi, Oreste Buonomo, Sergio Chimenti, Maria Sole Chimenti

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Because of the increased knowledge about the underlying cytokine network in psoriasis, selective systemic agents for the treatment of moderate-to-severe psoriasis have been developed during the past decade. The marked upregulation of JAK/STAT pathways in psoriasis and the identification of multiple key mediators in psoriasis pathogenesis that signal through JAK/STAT pathways led to investigation of JAK proteins as potential therapeutic targets for psoriasis treatment. A novel JAK-STAT inhibitor, tofacitinib, has been tested in preclinical studies for the treatment of psoriasis. Considering the satisfactory safety profile and the encouraging efficacy observed in the Phase II and Phase III trials, tofacitinib may represent an important therapeutic to be included into the psoriasis paradigm.
Lingua originaleEnglish
pagine (da-a)443-455
Numero di pagine13
RivistaExpert Review of Clinical Immunology
Stato di pubblicazionePubblicato - 2015


  • IL-23
  • Th17
  • psoriasis
  • small molecules
  • tofacitinib


Entra nei temi di ricerca di 'Tofacitinib for the treatment of moderate-to-severe psoriasis'. Insieme formano una fingerprint unica.

Cita questo